AI Prospecting for Zimmer Biomet Holdings
Company data:
Company size:
18000 employeesWebsite URL:
https://www.zimmerbiomet.comIndustry
Medical DevicesHeadquarters:
345 East Main Street, Warsaw, Indiana, United StatesInvestment round:
Publicly Traded (NYSE: ZBH)ARR:
$7 billionLatest news about Zimmer Biomet Holdings
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Zimmer Biomet reported a 4.0% increase in third-quarter 2024 net sales to $1.824 billion, with adjusted diluted earnings per share of $1.74. The company announced the commercial launch of the Z1™ Femoral Hip System, acquired OrthoGrid Systems Inc., and received FDA clearance for the Z1 Femoral Hip Stem[1][2][3].
Zimmer Biomet announced the broad commercial launch of the Z1™ Femoral Hip System at the 2024 AAHKS annual meeting, pairing it with the G7 Acetabular System. The company also highlighted its acquisition of OrthoGrid Systems Inc., integrating AI-powered surgical assistance technologies like OrthoGrid Hip AI[2][5].
Zimmer Biomet received FDA 510(k) clearance for the Persona® SoluTion™ Porous Plasma Spray (PPS®) Femur, a total knee implant component offering a cementless fixation alternative for patients with sensitivities to bone cement and/or metal, set for commercial availability in Q1 2025[3].
Open job positions at Zimmer Biomet Holdings
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
